What is claimed:

1. Use of a MEK inhibitor which is binimetinib or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating a cancer selected from renal cancer, melanoma and non-small cell lung cancer, wherein the medicament is to be used in combination with a PD-1 binding antagonist and wherein said combination of said MEK inhibitor and said PD-1 binding antagonist is not used in combination with a BRAF inhibitor.

2. Use of a MEK inhibitor which is binimetinib or a pharmaceutically acceptable salt thereof, and a PD-1 binding antagonist in the manufacture of a medicament for treating cancer.

3. The use of claim 1 or claim 2, wherein the cancer is renal cancer.

4. The use of claim 1 or claim 2, wherein the cancer is melanoma.

5. The use of claim 1 or claim 2, wherein the cancer is non-small cell lung cancer.

6. The use of any one of claims 1 to 5, wherein the PD-1 binding antagonist is an anti PD-1 antibody.

7. The use of claim 6, wherein the anti PD-1 antibody is nivolumab or a biosimilar thereof.

8. The use of claim 6, wherein the anti PD-1 antibody is pembrolizumab or a biosimilar thereof.

9. The use according to any one of claims 1-8, wherein the MEK inhibitor is crystallized binimetinib.

10. Binimetinib for use in treating cancer, wherein during treatment, a PD-1 binding antagonist is also to be used independently of the binimetinib.

11. Binimetinib, in combination with a PD-1 binding antagonist, for use in the treatment of cancer.